Misleading guidance from pharmacogenomic testing

Tahir Rahman; David M. Ash; John Lauriello; Roshni Rawlani

doi:10.1176/appi.ajp.2017.16121353

Misleading guidance from pharmacogenomic testing

Tahir Rahman, David M. Ash, John Lauriello, Roshni Rawlani

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	922-924
Number of pages	3
Journal	American Journal of Psychiatry
Volume	174
Issue number	10
DOIs	https://doi.org/10.1176/appi.ajp.2017.16121353
State	Published - Oct 1 2017

Access to Document

10.1176/appi.ajp.2017.16121353

Cite this

@article{e9a2376730014b98b0891fb0aa9d7c75,

title = "Misleading guidance from pharmacogenomic testing",

author = "Tahir Rahman and Ash, {David M.} and John Lauriello and Roshni Rawlani",

note = "Funding Information: From the Department of Psychiatry, University of Missouri School of Medicine, Columbia. Address correspondence to Dr. Rahman ([email protected]). Dr. Lauriello has served on an event monitoring board for a clinical trial through a contract with Janssen Pharmaceutica and the University of Missouri; he has served on advisory panels for Janssen, Otsuka, Reckitt Benckiser, Sunovion, and Teva; and he has overseen clinical research sites for Columbia University sponsored by Sunovion and for Florida Atlantic University sponsored by Otsuka. The other authors report no financial relationships with commercial interests. Received Dec. 6, 2016; revision received Feb. 14, 2017; accepted March 6, 2017.",

year = "2017",

month = oct,

day = "1",

doi = "10.1176/appi.ajp.2017.16121353",

language = "English",

volume = "174",

pages = "922--924",

journal = "American Journal of Psychiatry",

issn = "0002-953X",

number = "10",

}

TY - JOUR

T1 - Misleading guidance from pharmacogenomic testing

AU - Rahman, Tahir

AU - Ash, David M.

AU - Lauriello, John

AU - Rawlani, Roshni

N1 - Funding Information: From the Department of Psychiatry, University of Missouri School of Medicine, Columbia. Address correspondence to Dr. Rahman ([email protected]). Dr. Lauriello has served on an event monitoring board for a clinical trial through a contract with Janssen Pharmaceutica and the University of Missouri; he has served on advisory panels for Janssen, Otsuka, Reckitt Benckiser, Sunovion, and Teva; and he has overseen clinical research sites for Columbia University sponsored by Sunovion and for Florida Atlantic University sponsored by Otsuka. The other authors report no financial relationships with commercial interests. Received Dec. 6, 2016; revision received Feb. 14, 2017; accepted March 6, 2017.

PY - 2017/10/1

Y1 - 2017/10/1

UR - http://www.scopus.com/inward/record.url?scp=85031321205&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.2017.16121353

DO - 10.1176/appi.ajp.2017.16121353

M3 - Article

C2 - 28965468

AN - SCOPUS:85031321205

SN - 0002-953X

VL - 174

SP - 922

EP - 924

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

IS - 10

ER -

Misleading guidance from pharmacogenomic testing

Access to Document

Other files and links

Cite this